Transcend Capital Advisors LLC Purchases 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Transcend Capital Advisors LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 363,913 shares of the biopharmaceutical company’s stock after purchasing an additional 37,059 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Amicus Therapeutics were worth $3,428,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of FOLD. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics in the third quarter valued at about $26,000. Hazlett Burt & Watson Inc. raised its position in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Blue Trust Inc. raised its position in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI bought a new position in Amicus Therapeutics in the third quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Amicus Therapeutics during the third quarter worth about $55,000.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.07 on Friday. The business has a 50 day simple moving average of $9.56 and a 200 day simple moving average of $10.41. Amicus Therapeutics, Inc. has a one year low of $8.78 and a one year high of $14.02. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

FOLD has been the subject of a number of analyst reports. Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday. Guggenheim raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley restated an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.